| A prescription medicine for adults with chronic inflammatory demyelinating polyneuropathy (CIDP) |
|
|
|
Bustin’ a move
when the moment’s right. |
| that’s living VYVIDLY™ |
|
|
|
|
| What could living VYVIDLY mean for you? |
| It could mean saying yes to cutting a rug when your song comes on. |
| Explore the goals and results from the largest CIDP clinical study in history and see what’s possible when the risk of CIDP symptoms getting worse is reduced. |
|
| Discover what’s possible with VYVGART Hytrulo for CIDP |
|
Effectiveness established in 2 stages
 |
The effectiveness of VYVGART Hytrulo was established in 2 stages of a clinical study. Patients who had symptom improvements in stage A moved onto stage B. |
|
|
Reduced risk of CIDP getting worse
 |
The risk of arm and leg symptoms getting worse was 61% lower for patients taking VYVGART Hytrulo, compared to those who were given placebo. |
|
|
| 99% |
of eligible patients chose to be part of an extended safety study and receive VYVGART Hytrulo
(226 out of 228 patients) |
|
|
|
| Please see Important Safety Information below. |
|
|
|
|
| An established safety profile |
| Knowing what to expect when you’re considering a treatment is important. Learn more about the most common side effects with VYVGART Hytrulo. |
| The most common side effects of VYVGART Hytrulo are respiratory tract infection, headache, urinary tract infection, tingling sensation, muscle pain, and injection site reaction. |
| VYVGART Hytrulo may increase the risk of allergic reactions including rash, swelling under the skin, shortness of breath, and hives. It may also increase the risk of serious allergic reactions such as trouble breathing and decrease in blood pressure leading to fainting, as well as infusion-related reactions including increase in blood pressure, chills, shivering, and chest, abdominal, and back pain. These reactions can occur during or after treatment and can cause doctors to pause or, in some cases, stop treatment. |
|
|
|
|
|
|
| IMPORTANT SAFETY INFORMATION |
| Do not use VYVGART HYTRULO if you have a serious allergy to efgartigimod alfa, hyaluronidase, or any of the other ingredients in VYVGART HYTRULO. VYVGART HYTRULO can cause serious allergic reactions and a decrease in blood pressure leading to fainting. |
| VYVGART HYTRULO may cause serious side effects, including: |
| • |
Infection. VYVGART HYTRULO may increase the risk of infection. The most common infections for efgartigimod alfa-fcab-treated patients were urinary tract and respiratory tract infections. Signs or symptoms of an infection may include fever, chills, frequent and/or painful urination, cough, pain and blockage of nasal passages/sinus, wheezing, shortness of breath, fatigue, sore throat, excess phlegm, nasal discharge, back pain, and/or chest pain. |
| • |
Allergic Reactions (hypersensitivity reactions). VYVGART HYTRULO can cause allergic reactions such as rashes, swelling under the skin, and shortness of breath. Hives were also observed in patients treated with VYVGART HYTRULO. Serious allergic reactions, such as trouble breathing and decrease in blood pressure leading to fainting have been reported with efgartigimod alfa-fcab. |
| • |
Infusion-Related Reactions. VYVGART HYTRULO can cause infusion-related reactions. The most frequent symptoms and signs reported with efgartigimod alfa-fcab were high blood pressure, chills, shivering, and chest, abdominal, and back pain. |
|
| Tell your doctor if you have signs or symptoms of an infection, allergic reaction, or infusion-related reaction. These can happen while you are receiving your VYVGART HYTRULO treatment or afterward. Your doctor may need to pause or stop your treatment. Contact your doctor immediately if you have signs or symptoms of a serious allergic reaction. |
|
|
| Before taking VYVGART HYTRULO, tell your doctor if you: |
| • |
take any medicines, including prescription and non-prescription medicines, supplements, or herbal medicines, |
| • |
have received or are scheduled to receive a vaccine (immunization), or |
| • |
have any allergies or medical conditions, including if you are pregnant or planning to become pregnant, or are breastfeeding. |
|
| What are the common side effects of VYVGART HYTRULO? |
| The most common side effects in efgartigimod-alfa-fcab-treated patients were respiratory tract infection, headache, and urinary tract infection. Additional common side effects with VYVGART HYTRULO are injection site reactions, including rash, redness of the skin, itching sensation, bruising, pain, and hives. |
| These are not all the possible side effects of VYVGART HYTRULO. Call your doctor for medical advice about side effects. You may report side effects to the US Food and Drug Administration at 1‑800‑FDA‑1088. |
| What is VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc)? |
| VYVGART HYTRULO is a prescription medicine used for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) |
| Please see the full Prescribing Information for VYVGART HYTRULO and talk to your doctor. |
|
|
|
|
|
|
